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Abstract
Background: We aimed to test the antiproliferative effect of acetylsalicylic acid (ASA) on vascular smooth muscle cells
(VSMC) from bypass surgery patients and the role of transforming growth factor beta 1 (TGF-b1).
Methodology/Principal Findings: VSMC were isolated from remaining internal mammary artery from patients who
underwent bypass surgery. Cell proliferation and DNA fragmentation were assessed by ELISA. Protein expression was
assessed by Western blot. ASA inhibited BrdU incorporation at 2 mM. Anti-TGF-b1 was able to reverse this effect. ASA
(2 mM) induced TGF-b1 secretion; however it was unable to induce Smad activation. ASA increased p38
MAPK
phosphorylation in a TGF-b1-independent manner. Anti-CD105 (endoglin) was unable to reverse the antiproliferative
effect of ASA. Pre-surgical serum levels of TGF-b1 in patients who took at antiplatelet doses ASA were assessed by ELISA and
remained unchanged.
Conclusions/Significance: In vitro antiproliferative effects of aspirin (at antiinflammatory concentration) on human VSMC
obtained from bypass patients are mediated by TGF-b1 and p38
MAPK. Pre-surgical serum levels of TGF- b1 from bypass
patients who took aspirin at antiplatelet doses did not change.
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Introduction
Aspirin (Acetylsalicylic acid, ASA) exerts a significant improve-
ment of cardiovascular outcome [1,2]. Cardiovascular benefits
attributed to aspirin have been linked to its antiplatelet effect.
Nevertheless,somereportsdescribethedirectantiproliferativeeffect
of ASA on cultured vascular smooth muscle cells (VSMC) [3,4],
which may be related to the decreased carotid atherosclerotic size in
patients under ASA treatment [5]. This antiproliferative effect has
been linked to the cytokine Transforming Growth Factor-Beta
(TGF-b) in rat VSMC [4]. However, no data are available about its
link to the effect of ASA on VSMC from patients undergoing
coronaryarterybypassgrafting.TheassociationofASAandTGF-b
in human cardiovascular disease seems plausible, since decreased
levels of this cytokine are found in patients suffering unstable angina
and they can be restored by ASA treatment [6]. ASA has been
shown to decrease plasmatic concentrations of proinflammatory
cytokines (IL-6 and CRP) in this clinical condition [7].
The effects of TGF-b are complex and context-dependent. In
VSMC, its canonical pathway involves signalling by ALK-5
receptor, which phosphorylates the Smad family proteins and
translocate into the nucleus to regulate gene expression [8]. The
ALK-5/phospho-Smad2 (PSmad2)-dependent signalling pathway
has been linked to apoptosis in human VSMC [9]. Nevertheless, in
cultured VSMC the importance of TGF-b1-dependent p38
MAPK
signalling when TGF-b1 induces proliferation arrest in the
absence of apoptosis has equally been described [10]. Interestingly,
this antiproliferative but not apoptotic effect of ASA is observed
when both rat [4] and human [3] VSMC are incubated with
millimolar concentrations of ASA. ASA has been proven to
stimulate the p38
MAPK pathway in a wide variety of cell types and
this effect may be related to its antiproliferative effect [11]. We
aimed to demonstrate the effects of both TGF-b1 and the
p38
MAPK on the antiproliferative effect of ASA in human VSMC,
and the effect of clinical consumption of ASA in pre-operative
serum levels of TGF-b1.
Results
ASA decreases cell proliferation
ASA decreased cell number at the 2 mM concentration
(Figure 1, panel A). Moreover, an ASA-mediated decrease of
BrdU uptake was noted (Figure 1, panel B) for the concentration of
2 mM. The highest concentration of the drug proved unable to
increase apoptosis (Figure 1, panel C). This lack of effect was also
observed when LDH activity was assessed (Figure 1, panel D). In
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9800addition, when the cells were observed, they did not show any
morphological signs of apoptosis or necrosis after incubation with
2 mM ASA for 24 and 48 h (Figure 1, panels E, F and G).
Role of TGF-b1
Inhibition of DNA synthesis induced by ASA (2 mM) was
reversed by co-incubation with anti-TGF-b1 antibody (Figure 2,
panel A). To assess TGF-b1 secretion and thus reinforce TGF-b1
dependence, ELISA from cell conditioned media with ASA
(2 mM) was performed. Figure 2, panel B shows that ASA induces
TGF-b1 secretion compared to the control group, where levels
initially drop due to the change from serum-rich medium to
serum-free medium and subsequently increase due to cell culture
secretion (0-6 h). However, ASA (2 mM) was unable to induce
protein expression of TGF-b1 in a significant manner (Figure 2,
panels C and D). ASA (2 mM) was equally unable to increase
TGF-b-R-II transcription (Figure 2, panels E and F).
In ELISA experiments, incubation with ASA 2 mM yields a raw
TGF-b1 concentration of 100 pg/ml. When VSMC were cultured
with this concentration of exogenously added TGF-b1, it
mimicked the effect of ASA 2 mM, since it decreased BrdU
incorporation at 19 h (99.7866.889 vs 68.67678.99, P,0.01). Of
note, this concentration of TGF-b1 was equally unable to trigger
apoptosis at 24 h (1.060.08 vs 0.85060.080, P.0.05).
ASA does not induce the ALK-5/PSmad2 pathway
Since the ALK-5/PSmad2 pathway has been involved in the
decrease of the proliferation/apoptosis ratio induced by TGF-b1
[9], the antiproliferative effect of ASA was also studied in the
presence of the ALK-5 inhibitor SB-431542 (10 mM). The effect of
ASA was not inhibited when cells were treated with SB-431542
(Figure 3, panel A). Subcellular location of phosphorylated Smad2
(PSmad2) protein was assessed by confocal microscopy (Figure 3,
panel B). ASA enhanced total PSmad2 staining (Figure 3, panel
C). However, ASA proved unable to affect its nuclear recruitment.
(Figure 3, panel D). In order to rule out Smad2 activation,
PSmad2 expression was assessed by Western blot. As shown in
Figure 3, panels E and F, basal expression of PSmad2 was very low
and ASA (2 mM) was unable to increase it in a significant manner.
ASA induces TGF-b1-independent p38
MAPK
phosphorylation
The p38
MAPK inhibitor SB203580 (10 mM) abolished the
antiproliferative effect of ASA (Figure 4, panel A). We then tried
to assess whether ASA exerts its antiproliferative effect by
involving and autocrine loop of TGF-b1 and subsequent p38
MAPK
activation. Thus, p38
MAPK phosphorylation was assessed at 1, 3
and 6 h time, when TGF-b1 was secreted (Figure 2, panel B).
When the cells were incubated with ASA, an increase of p38
MAPK
phosphorylation was observed, reaching a maximum at 1 h
(Figure 4, panels B and C). However, neither anti-TGF-b1 (50 mg/
ml) nor the ALK-5 inhibitor SB-431542 (10 mM) had a significant
effect at 1 h (Figure 4, panels D and E).
ERK1/2
MAPK is not involved in the antiproliferative effect
of ASA
We measured the effect of aspirin in ERK1/2
MAPK phosphor-
ylation and its relation to the ASA-mediated antiproliferative
Figure 1. Effects of ASA on human vascular smooth muscle cell proliferation and death. Panel A: Cells were incubated with ASA at 0.5, 1
or 2 mM and counted. Panel B: Concentration-dependency of ASA effect on DNA synthesis. Panel C: Effect of ASA (2 mM) on DNA fragmentation.
Panel D: Effect of ASA (2 mM) on LDH activity. Panel E: Photomicrograph shows VSMC cultured in ASA-free10% FCS medium. Panel F: Effect of ASA
(2 mM, 24 h) on cell morphology. Panel G: Effect of ASA (2 mM, 48 h) on cell morphology. Bar graphs show the mean6S.E.M of n=4 experiments
(cell cultures from 4 different patients). *P,0.05, ***P,0.001.
doi:10.1371/journal.pone.0009800.g001
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MAPK inhibitor
PD98059 at 10 mM did not reverse the antiproliferative effect of
aspirin at 2 mM. Incubation with aspirin did not induce a higher
phospho-ERK1/2
MAPK expression (Figure 5, panels B and C).
CD105 is not involved in the antiproliferative effect of
ASA
Since CD105 or endoglin is an important co-receptor of the
TGF-b1 receptor system, we assessed whether CD105 was
involved in the antiproliferative effect of ASA. As shown in the
Figure 6, coincubation with anti-CD105 (1 mg/ml) was unable to
reverse the antiproliferative effect of the drug.
Therapeutics with aspirin does not increase serum levels
of TGF-b1
As shown in the Table 1, when bypass patients were given
aspirin at antiplatelet doses (75–300 mg), concentration of TGF-
b1 in the pre-surgical serum remained unchanged. Clinical and
biochemical characteristics of the patients are shown in Table 1.
Our patients showed a high presence of cardiovascular risk factors,
in accordance to advanced atherosclerotic disease.
Discussion
The most relevant findings of this work can be summarized as
follows: 1) At milimolar concentrations ASA has an antiprolifer-
ative effect on human VSMC from bypass patients; 2) This
antiproliferative effect is mediated by the release of TGF-b1;
3) The intracellular mechanism of ASA does not involve the
activation of Smad2 but the activation of p38
MAPK independently
of the TGF-b1; 4) The early activation of TGF-b1 and p38
MAPK
are able to trigger a maintained antiproliferative effect at 24 h; 5)
Serum levels of TGF-b1 are not changed in bypass patients who
take aspirin at antiplatelet doses. Thus, the present study is the first
report which demonstrates the role of TGF-b1 and MAP kinases
in the antiproliferative of ASA on human VSMC. Moreover, these
VSMC were obtained from severe atherosclerotic patients ongoing
bypass surgery, which highlights the potential importance of these
molecular mechanisms in samples obtained from the clinic.
An important finding of the present work is the inability of the
ALK-5 inhibitor SB-431542 to reverse the antiproliferative effect
of ASA, in contrast to the observed reversion by anti-TGF-b1.
This lack of effect of SB-431542 is accompanied by the failure of
ASA to induce PSmad2 expression in our cell model. Interestingly,
ALK-5 and Smad2-dependent pathways have been described to
mediate TGF-b1-induced apoptosis of rat [12] and human VSMC
[9], which coincides with the inability of ASA to trigger cell death
(Figure 1, panels C and D). At the same time, endoglin or CD105
is an accessory receptor of the TGF-b1 which has been closely
related to the ALK/Smad receptor system [8]. In our experi-
ments, anti-CD105 was unable to reverse the antiproliferative
effect of ASA (Figure 6). Thus, as a whole, our data suggest that
the ASA-inducedTGF-b1 signalling does not involve the classical
ALK/Smad system. Non-Smad pathways are emerging TGF-b1
signalling mechanisms which seem to play an important role in
VSMC cycle control [8]. The antiproliferative but not apoptotic
effect of ASA on human VSMC described in the present study
reproduces what reported elsewhere [3].
Figure 2. Role of TGF-b1 in the antiproliferative effect of ASA. Panel A: Anti-TGF-b1 (50 mg/ml) reversed the antiproliferative effect of ASA
(2 mM). Panel B: ASA-mediated secretion of TGF-b1. Panel C: representative Western blot expression of TGF-b1 after incubation with ASA 2 mM. Panel
D: quantification of Western blot experiments. Panel E: Representative RT-PCR blots for TGF-b-RII mRNA after incubation with ASA 2 mM. Panel F:
Quantification of RT-PCR experiments. Bar graphs show the mean6S.E.M of n=4 experiments (cell cultures from 4 different patients). **P,0.01,
***P,0.001.
doi:10.1371/journal.pone.0009800.g002
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increase in the cell culture conditioned media (Figure 2, panel B).
In a previous study, however, we found that aspirin was unable to
increase TGF-b1 secretion in a rat VSMC [4]. Inter-species
differences, in addition to the advanced age and atherosclerotic
evolution of our group of patients may mediate this difference.
COX-1, the major target of ASA, regulates exocytosis of platelet
granules and it might mediate VSMC secretion of TGF-b1 after
incubation with the drug [3].
Given that ALK-5/Smad2 pathway was not involved in the
antiproliferative effect of ASA we looked at another intracellular
pathway related with TGF-b1. The p38
MAPK inhibitor SB203580
significantly reduced the effect of ASA (Figure 4, panel A).
However, the activation of p38
MAPK was independent of TGF-b1
since neither the anti-TGF-b1 antibody nor the ALK-5 inhibitor
was able to block the effect of the drug (Figure 4, panel D and E).
These data confirm that the antiproliferative effect of ASA was
mediated by two independent mechanisms: a TGF-b1-dependent
(Figure 2, panel A) and a p38
MAPK-dependent mechanism
(Figure 4, panel A). This last mechanism involving p38
MAPK
may be mediated by the salicylic part of the molecule [3]. On the
other hand, aspirin-mediated increase in basal p38
MAPK and
decrease of other inflammation-related proteins such as ERK1/
2
MAPK has been reported [11,13]. This study suggests a non-
significant effect of basal ERK1/2
MAPK in the antiproliferative
role of aspirin (Figure 5, panels A, B and C).
The range of in vitro concentrations of ASA used in this study
was related to antiinflammatory doses [11]. Cardiovascular
benefits attributed to ASA are generally explained by its
antiplatelet action, due to its irreversible inhibition of platelet
COX-1 by irreversible acetylation of Ser 530 [14]. Nevertheless, in
vitro concentrations of the drug in cell culture media and clinical
doses of the drug cannot be correlated on an exact basis, since cell
culture models lack several pharmacokinetic phenomena such as
accumulation, bio-disposability and the existence of different
pharmacokinetics compartments. Normal doses of ASA for
cardiovascular purposes (such as 300 mg) are up to 10 times over
the optimal concentration of COX-1 inhibition [11]. Although
there is a proven in vitro antiplatelet activity in patients under ASA
treatment [15] the idea of additional mechanisms for ASA-
induced cardiovascular protection has been strengthened by some
findings about its antiinflammatory and antiproliferative effects
[3,4,11].
Benefits of CABG surgery are still dampened by its rate of graft
failure, which may be ameliorated by means of ASA therapy [16].
In-vessel graft failure determinants include endothelial damage,
Figure 3. ALK-Smad pathways do not mediate the antiproliferative effect of ASA. Panel A: The ALK-5 blocker SB-431542 (10 mM) did not
affect the antiproliferative effect of ASA (2 mM). Panel B: Representative images from cells treated with ASA (2 mM). Panel C: Quantitative analysis of
whole-cell intensity of fluorescence in treated versus untreated samples. Panel D: Quantitative analysis of nuclear/cytoplasmic intensity in both
groups. Panel E: representative Western blots of PSmad2 expression after incubation with ASA (2 mM). Panel F: Quantification of Western blot
experiments of PSmad2 after incubation with ASA (2 mM). Bar graphs show the mean6S.E.M of n=4 experiments (cell cultures from 4 different
patients). *P,0.01, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0009800.g003
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MAPK pathway is involved in the antiproliferative effect of ASA. Panel A: The p38
MAPK inhibitor SB203580 (10 mM)
reversed the antiproliferative effect of ASA (2 mM). Panel B: Representative blots of p38
MAPK phosphorylation after ASA incubation (2 mM) at several
time-points. Panel C: quantification of pooled Western blot experiments. Panel D: Representative blots show the role of the TGF-b pathway inhibitors
anti-TGF-b1 antibody (50 mg/ml) and SB-431542 (10 mM) on ASA-induced p38
MAPK phosphorylation, Panel E: quantification of pooled Western blot
experiments. a-T= anti-TGF-b1 antibody, SB= SB-431542. Bar graphs show the mean6S.E.M of n=4 experiments (cell cultures from 4 different
patients). *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0009800.g004
Figure 5. The ERK
MAPK pathway is not involved in the antiproliferative effect of ASA. Panel A: Effect of the ERK
MAPK blocker PD98059 when
addedtoASA(2 mM).DNAsynthesiswasassessedbyBrdUuptake,asstatedinMethods.PanelB:RepresentativeblotsofERK
MAPK phosphorylation (2 mM).
Panel C: Quantification of pooled results. Bar graphs show the mean6S.E.M of n=4 experiments (cell cultures from 4 different patients). ***P,0.001.
doi:10.1371/journal.pone.0009800.g005
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in vitro millimolar concentration relate to the ones achievable in vivo
by using clinical doses of the drug. At antiinflammatory doses,
ASA concentration in plasma reaches from 0.95–1.9 mM, with a
concentration of free drug of 250 mM. Since incubation media
contains 10% serum, millimolar in vitro concentration has been
regarded as related to anti-inflammatory dose [11], although the
concept that drug concentrations in cell culture media mimic the
ones obtained from clinical plasma cannot be demonstrated.
Nevertheless, it is clear that high anti-inflammatory doses of
aspirin may produce an increase of undesirable effects. On the
other hand, the at least equal efficacy of low-dose aspirin
(75–150 mg) compared to higher ones for long-term cardiovascu-
lar treatment is sustained by strong evidence [2]. Moreover, a
controlled clinical trial to compare aspirin at 50 and 900 mg did
not find any difference of re-occlusion after aortoiliac and
femoropopliteal percutaneous transluminal angioplasty, whereas
the high dose group had a higher rate of gastrointestinal side
effects [18].
Platelets play an essential role in atherosclerosis not only from a
haemostatic point of view but also by acting as direct inflammatory
mediators [19]. A potential way to enhance the therapeutical
benefit of ASA at the same time high dose-related adverse effects
are avoided may be based on the synergistic use of other
antiplatelet agents such as clopidrogrel. A recent large multicentric
trial did not observe a significant advance of combined treatment
for cardiovascular prevention in atherothrombotic or high-risk
patients [20]. However, evidence suggests a significant clinical
improvement in myocardial infarct patients treated with both
drugs [21]. Combination therapy seems to exert a significant
benefit in bypass patients [22]. Whether these synergistic clinical
benefits take place, at least in part, through antiinflammatory
cytokine pathways and the role of platelets when this effect is
considered will be the subject future research.
In conclusion, in the present study we show that at in vitro
antiinflammatory concentrations ASA exerts a TGF-b1and
p38
MAPK-dependent antiproliferative effect on human VSMC.
At the same time, however, aspirin therapy at antiplatelet doses
does not change the serum levels of TGF-b1 in our clinical sample.
Translational strategies in order to extend the in vitro additional
benefits of aspirin to the clinical scenario will be the subject of
further research.
Materials and Methods
Ethics Statement
Clinical data were obtained from bypass surgery patients at the
Cardiac Surgery Service (Hospital Clinico San Carlos, Madrid,
Spain). Exclusion criteria were age$80, inflammatory co-morbid-
ities, end-stage renal disease and cancer. The study was conducted
according to the Declaration of Helsinki. The study was approved
by the Local Ethical Committee (Hospital Clinico San Carlos,
Universidad Complutense, Madrid, Spain). In addition, patients
gave written informed consent. The internal mammary artery is
the vessel of choice for coronary artery bypass grafting, since this
vessel is free from atherosclerotic lesions. Experiments were only
made with remaining samples after surgery.
Cell cultures
VSMC from internal mammary arteries obtained from our
clinical sample were cultured from explants in RPMI (Life
Technologies, Barcelona, Spain) containing 10% foetal calf serum
(FCS). Cells exhibited typical ‘‘hill and valley’’ morphology and
were stained with a monoclonal anti-smooth a-actin. Cells at
passages 3–5 were used (4000 cells/cm
2). VSMC were obtained
from the internal mammary arteries following the explant
technique. Cell cultures took a minimum of 1–2 months before
going viable. During all that time, VSMC were incubated in
aspirin-free medium.
Cell counting
Cells were seeded onto 24-well plates and allowed to attach for
24 h. They were then treated with ASA at 0.5, 1 or 2 mM. After
24 h, they were detached with trypsin and counted on a
Neubauer’s chamber.
Figure 6. The antiproliferative effect of ASA is independent of
endoglin. Effect of anti-CD105 (anti-endoglin, 1 mg/ml) on the
antiproliferative effect of ASA (2 mM). Bar graphs show the mean6
S.E.M of n=4 experiments (cell cultures from 4 different patients).
***P,0.001.
doi:10.1371/journal.pone.0009800.g006
Table 1. Clinical characteristics of the study groups.
No Aspirin
n=57
Aspirin takers
n=64 P
Age (years) 64.469.2 64.668.8 0.88 *
Female (%) 9 (7) 8 (6.6) 0.60
{
Hypertension (%) 29 (24) 38 (31) 0.35
{
Diabetes Mellitus (%) 18 (15) 36 (29) 0.006
{
Current smokers (%) 23 (19) 15 (12) 0.045
{
Statin takers (%) 22 (18) 42 (35) 0.002
{
Total Cholesterol (mg/dl)
¥ 161.6653 146.3638 0.05 *
LDL-cholesterol (mg/dl)
¥ 88641 77632 0.09 *
HDL-cholesterol (mg/dl) 37.5613.5 38.5610.25 0.78
1
Triglycerides (mg/dl)
¥ 147.6668 128.2664 0.05 *
C- reactive Protein (mg/l) 4.3683 . 6 65 0.39
1
TNF-a (pg/dl) 6.362.7 6.063.2 0.39
1
TGF-b1 (ng/ml) 43614.4 39612.3 0.11 *
TGF-b1/No.platelet
¥ 0.1760.8 0.1760.6 0.99 *
Data represent the mean6S.D (
¥ Harmonic mean). Data with non-parametric
distribution (HDL-cholesterol, C-reactive protein and TNF-a) are shown as
median6IQR.
*Student t test.
{Squared-chi test.
1Mann-Whitney U test.
Significance is assumed for a P,0.05.
doi:10.1371/journal.pone.0009800.t001
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Lactate dehydrogenase (LDH) activity was assessed as a
measurement of cytotoxicity according to a method previously
described [23]. Briefly, cells were incubated in the presence or
absence of ASA at 2 mM. After 24 h lactate-dehydrogenase
(LDH) activity was measured in the supernatant by pyruvate decay
at 340 nm.
DNA fragmentation
Cellular DNA fragmentation was measured with a commercial
ELISA kit (Roche-Boerhinger, Spain). Proliferating cells in 96-well
plates were labelled with 10 mM BrdU overnight and treated with
ASA. They were incubated with the kit lysis buffer (BSA, EDTA,
and TweenH 20) for 30 min at room temperature. Soluble BrdU-
labelled DNA fragments were quantified using the ELISA kit.
Cell morphology
VSMC were plated on F25 cell culture flasks (Nunc, Roskilde,
Denmark), and allowed to attach overnight. They were then
incubated with ASA-free 10% FCS medium or with ASA 2 mM
for 24 or 48 h. Images were obtained using a DMT4000-B
inverted microscope (Leica, Wetzlard, Germany) and registered by
a FE-3000 digital camera (Olympus, Tokyo, Japan).
BrdU incorporation
VSMC were plated onto 96-well plates and allowed to attach
for 24 h. The cells were serum-starved for 32 h in 0.4% FCS
containing medium in order to synchronize the cells in G0/G1.
They were then treated with 10% FCS-containing medium with
ASA (0.5, 1 or 2 mM) for 19 h, and loaded with BrdU (10 mM) for
the last 3 h of treatment. BrdU incorporation was measured by an
ELISA kit (Amersham Life Science, Barcelona, Spain). Inhibitors
were: anti-TGF-b1a t5 0 mg/ml (R&D Systems, Minneapolis,
MN), the p38
MAPK inhibitor SB203580 (10 mM), the ERK
MAPK
inhibitor PD98059 (10 mM), the ALK-5 blocker at 10 mM SB-
431542 (Tocris, Bristol, UK), and anti-CD105 at 1 mg/ml (BD
Bioscience, Franklin Lakes, USA), as described [24].
ELISA measurements from cell conditioned media
Total TGF- b1 levels were determined by a TGF-b1-specific
ELISA, (R&D Systems, Minneapolis, MN). Cells were incubated
with ASA 2 mM in serum-free medium (RPMI+ 0.2% bovine
serum albumin + PDGF-BB at 10 ng/ml).
Reverse transcription PCR (RT-PCR)
Sensitivity of VSMC cultures to exogenous TGF-b1 is strongly
associated with TGF-b-R-II expression [25]. We aimed to assess
this parameter by RT-PCR. Total RNA was extracted using a
commercial kit with DNase (RNeasy Mini kit, Qiagen, Spain).
RT-PCR was performed using the Titan-one-tube RT-PCR
(Boehringer, Mannheim, Germany). cDNA was obtained by
reverse transcription at 50uC (30 min) and 95uC (5 min). The
TGF-b-R-II gene was amplified using specific conditions, as
described [26]. Oligonucleotides are listed below:
TGF-b-R-II forward primer: CTACAAGGCCAAGCTGAA-
GC
TGF-b-R-II reverse primer: AGCCATGGAGTAGACATC-
CG
GAPDH forward primer: CGATGCTGGCGCTGAGTA
GAPDH reverse primer: CGTTCAGCTCAGGGATGACC
Thermal profile used a BioRad thermal cycler for denaturation
at 95uC for 1 min, annealing at 55uC for 1 min, and extension at
72uC for 1 min (23 cycles).
Confocal microscopy
Cells were cultured in the presence or absence of ASA 2 mM
from 1 to 6 h. The cells were washed with PBS, fixed for 20 min in
4% paraformaldehyde in PBS and permeabilized with 0.4%
triton-x100 for 30 min at room temperature. After blocking with
3% BSA in PBS, the cells were then incubated with rabbit
polyclonal anti-PSmad2 (Calbiochem, Schwabach, Germany), at
1:100 for 1 h, following by incubation with goat anti-rabbit Alexa
568H (1:100, Molecular, Probes, 1 h). Images were captured using
a Leica-TCS-SP2 inverted microscope. Intensity was analyzed by
Image J.
Western blot
Cells were treated with ASA 2 mM in 10% FCS-containing
medium (1 to 6 h). They were washed with ice-cold PBS, and lysed
on ice with 200 ml lysis buffer (10% glycerol, 2.3% SDS, 62.5 mM
Tris, pH 6.8 150 mM NaCl, 10 mM EDTA, 1 mg/ml eupeptic,
1 mg/ml pepstatin, 5 mg/ml chymostatin, 1 mg/ml aprotinin,
1 mM phenylmethylsulphonyl fluoride) and boiled for 5 min.
Equal amounts of protein were run on 10% SDS-polyacrylamide
electrophoresis, transferred to polyvinylidene difluoride (PVDF)
membranes (Immobilon-P, Amersham, Madrid, Spain), and
blocked overnight at 4uC in blocking solution (5% skimmed milk
in TBS-T: 25 mM Trizma base, 75 mM NaCl, pH 7.4, 0.1% v/v
TweenH 20). Blots were incubated with agitation at 4uC overnight
with anti-phospho-p38
MAPK or anti-p38
MAPK (both of them from
Calbiochem, Schwabach, Germany) at 1:1000 in TBS-T. Blots
were incubated for 1 h at room temperature with horseradish
peroxidase anti-rabbit-IgG (Santa Cruz Biotechnology, CA,
1:10000). Protein was visualized with ECL (Amersham Bioscienc-
es, Barcelona, Spain).
Similar procedures were used for Western blot expression
assessment of TGF-b1 (anti-TGF-b1, Santa Cruz, Biotechnolo-
gies, Santa Cruz, USA), phospho-Smad (anti-Smad2, phospho-
specific, Calbiochem, Schwabach, Germany) and phospho-ERK
(anti-active ERK
MAPK, Calbiochem, Schwabach, Germany).
Smooth muscle a-actin was used as a housekeeping protein
(anti-a-actin, Sigma-Aldrich, Madrid, Spain). All the primary
antibodies were diluted at 1:1000 in TBS-T.
Determination of serum TGF-b1
Pre-surgical serum was taken from the patients who were
chronically treated with aspirin at antiplatelet doses (75–300 mg
daily, n=64), or not (n=57). Total levels of TGF-b1 (active plus
acid-activatable) were assessed by ELISA (R&D systems, Minnea-
polis, MN, USA). This kit proved highly reproducible in a large
comparative study of several ELISA kits for TGF-b [27].
Statistical analysis
A statistical analysis of the data was carried out by a Student’s t
test, Fisher exact test, or by a one-way ANOVA when necessary.
Drugs and reagents
Acetylsalicylic acid (ASA) was purchased from sigma (Madrid,
Spain), and dissolved in the cell cultured medium. Specific
pharmacologic inhibitors (all from Tocris, Bristol, UK) of
p38
MAPK (SB203580), ERK
MAPK (PD98059) and ALK-5 (SB-
431542) were preincubated at 10 mM 1 h before the stimulus was
added and then they were coincubated, again at 10 mM, for the
indicated time points. This strategy has been demonstrated to
totally inhibit these pathways [28,29,30]. Anti-TGF-b1 (R&D
systems, Madrid, Spain) was coincubated at 50 ng/ml, since this
approach was able to totally inhibit TGF-b1 in vascular smooth
ASA and TGFb in Human Cells
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9800muscle cells [4,31]. Anti-CD105 (BD Bioscience, Franklin Lakes,
USA) was coincubated at 1 mg/ml in order to totally block
CD105, as described [24].
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